RxDoctor Payments Data

John Miller

Family · New Lexington, OHNPI 1144239096

Payments from drug & device makers

$5,083in general payments, 2019–2025

Across 308 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$980
  • Amgen$274
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$260
  • Takeda Pharmaceuticals U.S.A., Inc.$146
  • Abiomed$121
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,083 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$169
Medicare patients
19
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide75$83,765
JardianceEmpagliflozin53$70,282
FarxigaDapagliflozin Propanediol45$57,644
EliquisApixaban45$47,224
OzempicSemaglutide25$42,341
XareltoRivaroxaban59$40,163
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$38,758
MounjaroTirzepatide25$34,791
JanuviaSitagliptin Phosphate38$30,499
VraylarCariprazine Hcl17$28,447
LinzessLinaclotide32$27,752
Nurtec OdtRimegepant Sulfate12$23,278
RexultiBrexpiprazole15$22,520
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$21,775
Tresiba Flextouch U-200Insulin Degludec13$19,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$47$118,556100 claims
AstraZenecaFarxiga, Breztri Aerosphere$980$96,40186 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$75$91,67378 claims
PfizerEliquis, Nurtec Odt$87$70,50157 claims
AbbVieVraylar, Linzess, Synthroid$1,432$58,53482 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$40$46,89773 claims
Novo NordiskOzempic$77$42,34125 claims
MerckJanuvia, Dulera$104$36,16655 claims
Otsuka America Pharmaceutical, Inc.Rexulti$101$22,52015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in New Lexington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →